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Phosphorylation of 20 kD myosin light chain (MLC) is a critical process in eliciting smooth muscle contraction. Excitatory 
receptor agonists increase the extent of MLC phosphorylation by both activating myosin light chain kinase (MLCK) and inhibiting 
myosin phosphatase (MP). Activation of MLCK is dependent on Ca2+ and calmodulin, while inhibition of MP is dependent on 
the small guanosine triphosphatase Rho and Rho kinase. Receptor agonists were previously shown to induce Rho activation via 
the heterotrimeric G12/13 protein, largely in non-muscle cells. We recently discovered the novel Ca2+-dependent activation of 
Rho in vascular smooth muscle. This Ca2+-dependent Rho activation mechanism operates upon stimulation of vascular smooth 
muscle by either membrane depolarization or Gq-coupled vasoconstrictor receptors. Thus, Ca2+ induces MLC phosphorylation 
through both MLCK stimulation and MP inhibition. We found that phosphoinositide 3-kinase class II α isoform (PI3K-C2α) is 
involved in the Ca2+-dependent Rho activation and MP inhibition. PI3K-C2α appears to participate in regulation of vascular 
Rho activity and tone in vivo. These observations also indicate that PI3Ks exert isoform-specific effects on vascular tone through
mechanisms involving regulation of endothelial nitric oxide production and smooth muscle MP activity. 
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INTRODUCTION
 In smooth muscle including vascular smooth muscle, binding 
of excitatory receptor agonists to specific cell surface receptors,
most of which belong to the seven membrane-spanning 
type of G protein-coupled receptors, leads to activation of 
phospholipase C and gating of Ca2+ channels on the plasma 
membrane (1,2). The activation of phospholipase C produces 
the two second messengers, inositol-1,4,5-trisphosphate and 
1,2-diacylglycerol. Inositol-1,4,5-trisphosphate induces Ca2+ 
release from the intracellular Ca2+ pool, which, together with 
stimulated Ca2+ influx across the plasma membrane, causes an
increase in the intracellular free Ca2+ concentration ([Ca2+]i) 
(1-3). An increase in [Ca2+]i activates the Ca2+/calmodulin-
dependent enzyme myosin light chain kinase (MLCK), which 
phosphorylates the 20 kD myosin light chain (MLC), leading 
to initiation of a contractile response (4). An increase in the 
membrane content of 1,2-diacylglycerol leads to activation 
of protein kinase C, which activates a contractile mechanism 
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independently of or synergistically with an increase in the 
[Ca2+]i (Fig. 1) (1,3).
Phosphorylation state of MLC is determined by the activities 
of the de-phosphorylating enzyme myosin phosphatase (MP) 
as well as by the phosphorylating enzyme MLCK (5,6). The 
smooth muscle-specific MP consists of three subunits: 38 kD
catalytic subunit (PP1δ), 110 kD myosin targeting regulatory 
subunit (MYPT1/MBS) and 20 kD regulatory subunit (M20) 
(Fig. 2) (7). Recent evidence indicates that the activity of MP 
is regulated by both constrictors and relaxants; constrictors 
inhibit MP activity whereas relaxants stimulate it (3,5,6). 
Thus, excitatory receptor agonists such as noradrenaline and 
endothelin not only activate MLCK, but also inhibit MP, 
resulting in efficient phosphorylation of MLC. Conversely,
relaxants such as the cyclic GMP-elevating natriuretic peptides 
inhibit MLCK and stimulate MP, resulting in an effective 
reduction of MLC phosphorylation (Fig. 1). Accumulated data 
showed importance of the small G protein Rho as a switching 
Figure 1. The signaling mechanisms for smooth muscle contraction. Vasoconstrictors such as noradrenaline (NA) acting on 
α1 receptors, endothelin-1 (ET-1), and thromboxane A2 (TXA2) act on G protein-coupled receptors to stimulate phospholipase 
C (PLC) and Rho. PLC stimulation leads to Ca2+-mobilization and accumulation of membrane 1,2-diacylglycerol (DAG), 
resulting in the activation of the calmodulin-dependent enzyme myosin light chain kinase (MLCK) and protein kinase C (PKC). 
MLCK phosphorylates MLC and initiates contraction. Rho activation leads to myosin phosphatase (MP) inhibition, potentiating 
Ca2+-dependent MLC phosphorylation. PKC contributes to contraction through inhibition of MP and/or independently of MP. 
Vasodilators such as nitric oxide (NO), cyclic nucleotides cAMP and cGMP, NA (acting on β2 receptors), and prostacyclin (PGI2) 
inhibit MLC phosphorylation and contraction through decreasing the intracellular Ca2+ concentration and stimulation of MP. 
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molecule for regulating MP activity (3,8). In fact, excitatory 
receptor agonists induce activation of Rho in smooth muscle. 
In non-muscle cells, Rho regulates actin cytoskeletal assembly, 
controlling cell shape changes, migration and adhesion (9). In 
many cell types, a particular family of the heterotrimeric G 
proteins named G12/13 plays an important role in the regulation 
of Rho activity (10). Unexpectedly, we recently discovered 
that membrane depolarization induced Rho activation in a 
Ca2+-dependent manner, as potently as excitatory receptor 
agonists (11). This discovery provided considerable insight 
into understanding the regulatory mechanisms of MP and 
Ca2+-dependent contraction in smooth muscle. In this review, 
we will focus on the mechanisms of Rho regulation and Rho-
dependent MP inhibition in vascular smooth muscle, with 
particular emphasis on the novel Ca2+-dependent Rho and MP 
regulation mechanism. 
MOLECULAR MECHANISMS OF RHO-MEDIATED CALCIUM 
SENSITIZATION 
The development of membrane-permeabilized smooth 
muscle preparation contributed to our understanding of 
contractile mechanisms. In smooth muscle permeabilized 
with staphylococcal α-toxin and β-escin, excitatory receptor 
agonists including phenylephrine and thromboxane A2 
potentiated contraction at a constant [Ca2+]i, thus sensitizing 
contraction to Ca2+ (12,13). This potentiation of contraction 
was accompanied by an increase in the extent of MLC 
phosphorylation. The potentiating actions of receptor agonists 
required GTP, and were mimicked and inhibited by the 
non-hydrolyzable guanine nucleotides, GTPγS and GDPβS, 
suggesting the involvement of a G protein in the potentiation 
of MLC phosphorylation and contraction. The first evidence
for the role of Rho in smooth muscle contraction was provided 
by the observation that GTPγS-induced enhancement of Ca2+-
induced contraction in permeabilized vascular smooth muscle 
was abolished by Staphylococcal exoenzyme epidermal cell 
differentiation inhibitor (EDIN) and Clostrium botulinum 
exotoxin C3 (14), both of which specifically ADP-ribosylate
and inactivate Rho. However, it was unknown how Rho was 
involved in smooth muscle contraction. We demonstrated 
for the first time that pretreatment of permeabilized vascular
smooth muscle cells with C3 completely inhibited GTPγS 
enhancement of Ca2+-induced MLC phosphorylation 
(8), indicating that Rho was involved in Ca2+-induced 
MLC phosphorylation. Our observation implied the two 
possibilities, i.e. Rho might somehow potentiate MLCK-
catalyzed phosphorylation of MLC and/or Rho might inhibit 
MP-catalyzed de-phosphorylation of MLC. We pursed both 
possibilities and discovered that Rho mediated inhibition of 
MP but not potentiation of MLCK activity, thus resulting in 
potentiation of MLC phosphorylation (8,15) (Fig. 1). 
Active Rho directly binds to and regulates activities of 
several target proteins, which mediate many of Rho actions. 
These include the serine/threonine kinase Rho kinase/ROCK/
ROK, protein kinase N (PKN) and Citron kinase, and the 
non-kinase proteins mDia, Rhotekin and Rhophilin (9,16). 
Kimura et al (17) demonstrated that Rho kinase, but not PKN, 
phosphorylated the 110 kD MYPT1 subunit of purified myosin
phosphatase holoenzyme in vitro. Importantly, Rho kinase-
catalyzed phosphorylation of MYPT1 decreased phosphatase 
activity in vitro. Feng et al (18) identified Thr695 of MYPT1 
(numbering of chicken M133 isoform) as an inhibitory 
phosphorylation site. Rho kinase also phosphorylates MYPT1 
at Thr850 phosphorylation, which is shown to inhibit the 
binding of MP to myosin (19). Recent investigations (20,21) 
demonstrated that receptor agonists increased the extent of 
MYPT1 phosphorylation more definitely at Thr850 rather than 
at Thr695. We showed that the two structurally different Rho 
kinase inhibitors Y27632 and HA1077 abolished GTPγS-
induced potentiation of Ca2+-induced MLC phosphorylation 
in permeabilized smooth muscle cells, but not MLC 
phosphorylation induced by Ca2+ alone (15). Moreover, we 
found that HA1077 abolished GTPγS-induced inhibition of 
MP activity by the immunoprecipitation-phosphatase assay 
in vivo. The prevention of GTPγS-induced MP suppression 
by the Rho kinase inhibitor was accompanied by inhibition 
of GTPγS-induced MYPT1 phosphorylation although the 
phosphorylation site of MYPT1 was not determined (15). 
Recent investigatons (20,21) demonstrated that the Rho kinase 
inhibitors suppressed MYPT1 phosphorylation at Thr850 in 
vivo. Altogether, these observations indicate that Rho kinase 
mediates Rho-dependent MP inhibition through mechanisms 
involving MYPT1 phosphorylation in smooth muscle (Fig. 
2). 
The inhibitory phosphorylation site of MYPT1 (Thr695), 
was also shown to be phosphorylated in vitro by other kinases 
including ZIP/MYPT1-kinase (22) and integrin-linked kinase 
(ILK) (23). However, it is not known whether these kinases are 
involved in regulation of smooth muscle myosin phosphatase 
activity in vivo. It is either unknown whether Rho is somehow 
linked to regulation of activities of these kinases.
Protein kinase C-potentiated phosphatase inhibitor of 17 kD 
(CPI-17) is an endogenous smooth muscle-specific inhibitor
protein for myosin phosphatase (24). In particular, CPI-17 
is abundantly expressed in vascular smooth muscle. The 
phosphatase-inhibitory activity of CPI-17 is very low in its non-
16
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phosphorylated state and becomes 1000-fold stimulated when 
phosphorylated at Thr38 in vitro. Excitatory receptor agonists 
increased Thr38 phosphorylation of CPI-17 in smooth muscle 
(25), suggesting that CPI-17 participates in Ca2+-sensitization. 
CPI-17 was shown to be phosphorylated in vitro by several 
protein kinases, including protein kinase C (24), Rho kinase, 
PKN, ZIP/MYPT1-kinase and ILK. Protein kinase C inhibitors 
partially inhibited agonist-induced phosphorylation of CPI-
17 at Thr38 with inhibition of contraction (25). Rho kinase 
inhibitors also reduced agonist-induced phosphporylation of 
CPI-17 (26). These observations suggest that CPI-17 becomes 
active as a MP inhibitor through its phosphorylation by 
protein kinases including Rho kinase and protein kinase C, 
participating in MP inhibition (Fig. 2).
REGULATION OF RHO BY EXCITATORY AGONISTS
Despite accumulation of the observations showing the 
importance of the Rho-signaling pathway in the regulation 
of smooth muscle contraction, no direct effect of excitatory 
agonists on Rho activity in smooth muscle was yet 
demonstrated. Rho cycles between a GDP-bound inactive 
state and a GTP-bound active state, like Ras (9). We recently 
developed a new biochemical assay which employs a 
recombinant RhoA-binding protein, Rhotekin, for determining 
amounts of active GTP-bound form of RhoA (GTP-Rho) in 
smooth muscle tissues (27). In rabbit aortic smooth muscle, the 
thromboxane A2 mimetic U46619, which induced a sustained 
contractile response, caused a sustained rise in the amount of 
GTP-Rho in a dose-dependent manner with an EC50 value 
Figure 2. Molecular mechanism of negative regulation of myosin phosphatase (MP). The GTP-bound, active form of Rho induces 
Rho kinase activation, which leads to phosphorylation of the MP regulatory subunit MYPT1 at Thr850 and probably Thr695 as 
well as the MP inhibitor protein CPI-17 at Thr38. It is not totally clear whether Rho kinase directly phosphorylates MYPT1 or 
indirectly stimulates phosphorylation through activation of other kinases and/or inhibition of phosphatase. The other protein 
kinases including ZIP/MYPT1 kinase, ILK and protein kinase C may also be involved in phosphorylation of MYPT1 at Thr695 and 
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similar to that for the contractile response. U46619-induced 
Rho activation was thromboxane A2 receptor-mediated and 
reversible. Other agonists including noradrenaline, serotonin, 
histamine and endothelin-1 also stimulated Rho, albeit to a 
lesser extent than U46619. In contrast, angiotensin II and 
phorbol 12,13-dibutyrate failed to increase GTP-Rho. The 
tyrosine kinase inhibitor genistein substantially inhibited Rho 
activation by these agonists, except for endothelin-1. Thus, the 
magnitude and mode of agonist-induced Rho activation does 
not appear to be uniform among agonists. 
The cycling of Rho between the GTP-bound active and 
GDP-bound inactive states is under the tight regulation by the 
two major groups of proteins, guanine nucleotide exchange 
factors (GEFs) and GTPase-activating proteins (GAPs) (9,28). 
Previous studies, largely on non-muscle cells, demonstrated 
that stimulation with G protein-coupled receptor agonists 
including lysophosphatidic acid, endothelin-1 and thrombin 
induced Rho activation, which was mediated through the 
receptor coupling to the G12/13 family of the heterotrimeric G 
proteins (29). Indeed, direct physical and functional interaction 
of Gα12/13 with a group of structurally related GEFs that act 
on Rho (RhoGEFs) was demonstrated (30). More recent 
studies (30,31) showed that Gq also had the ability to mediate 
stimulation of Rho, but the signaling pathway that mediates 
Gq-mediated Rho stimulation is still incompletely understood 
although a Gαq-RhoGEFs interaction was observed. In cultured 
vascular smooth muscle cells, the expression of activated 
forms of Gα12 and Gα13 but not Gαq was shown to induce a 
contraction that was inhibited by C3 toxin and a Rho kinase 
inhibitor, whereas the expression of dominant negative forms 
of Gα12 and Gα13 inhibited receptor agonist-induced, C3 
toxin- and Rho kinase inhibitor-sensitive contraction (10). 
Thus, these observations indicated that G12/13 mediates Rho- 
and Rho kinase-dependent contraction in receptor agonist-
stimulated cultured vascular smooth muscle cells. However, 
our observations described above suggest that more than a 
single mechanism for activating Rho might be operating in 
smooth muscle. 
CALCIUM-DEPENDENT RHO ACTIVATION AND MYOSIN 
PHOSPHATASE INHIBITION
We recently found a novel, Ca2+-dependent mechanism for 
Rho activation in vascular smooth muscle. High KCl-induced 
membrane depolarization caused sustained increases in 
GTP-Rho with stimulation of MYPT1 phosphorylation in 
rabbit aortic smooth muscle, as well as the receptor agonist 
noradrenaline (11). Membrane depolarization-induced Rho 
activation was totally Ca2+-dependent. Thus, KCl-induced 
Rho activation was inhibited by either removal of extracellular 
Ca2+ or addition of a dihydropyridine Ca2+ channel antagonist. 
In vascular smooth muscle cells, ionomycin-induced Ca2+ 
mobilization produced Rho activation with stimulation of 
MYPT1 phosphorylation and MLC phosphorylation, which 
was suppressed by the expression of a dominant negative RhoA 
mutant, N19RhoA. The Rho kinase inhibitors HA1077 and 
Y27632 inhibited both contraction and MLC phosphorylation 
induced by KCl as well as noradrenaline in rabbit aortic smooth 
muscle, with similar dose-response relationships. Thus, Ca2+-
dependent Rho activation contributed to MP inhibition and 
resultant MLC phosphorylation in a Rho kinase-dependent 
manner.
Excitatory receptor agonists induce an increase in the [Ca2+]i 
(32). This suggests the possibility that receptor agonist-induced 
Rho activation might also be dependent on Ca2+ although 
G protein-coupled receptors were shown to mediate Rho 
activation via G12/13 in vascular smooth muscle cells (10) and 
non-muscle cells (29). Excitatory receptor agonists mobilize 
Ca2+ from both the intracellular and extracellular pools. The 
combination of extracellular Ca2+ removal and depletion of the 
intracellular Ca2+ store by using caffeine pretreatment almost 
completely abolished agonist-induced Ca2+ mobilization in 
smooth muscle (11). Rho stimulation and contraction induced 
by noradrenaline and thromboxane A2 analogue U46619 was 
inhibited by this procedure, indicating that receptor agonist-
induced Rho activation was Ca2+-dependent. Intriguingly, 
noradrenaline- and U46619-induced Rho activation was Ca2+-
dependent to a varying degree: the Ca2+-depletion procedure 
totally abolished noradrenaline-induced Rho activation whereas 
it only partially inhibited U46619-induced Rho activation. 
Thus, U46619-induced Rho activation was less dependent on 
Ca2+. The results, together with the previous observation that 
U46619 is less effective in mobilizing Ca2+ (33), suggest that 
U46619-induced Rho activation is more strongly dependent on 
G12/13 than on noradrenaline. Most likely, the Ca2+-dependent 
mechanism for activating Rho operates in cooperation with 
a G12/13-mediated mechanism. Because Gq mediates Ca2+-
mobilization via activation of phospholipase C, multitudes of 
heterotrimeric G protein-mediated signaling pathways likely 
regulate Rho activity in excitatory receptor agonist-stimulated 
vascular smooth muscle (Fig. 3). 
It was unknown how Ca2+ is involved in Rho regulation 
in smooth muscle. During our investigation into the 
molecular mechanisms of Ca2+-dependent Rho activation, 
we found that phosphoinositide 3-kinase (PI3K) inhibitors 
suppressed membrane depolarization-induced Rho activation 
and contraction with suppression of MYPT1 and MLC 
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phosphorylation (34). The structurally different two PI3K 
inhibitors wortmannin and LY294002 exerted similar extents 
of maximal inhibition for contraction and Rho activation, 
suggesting that inhibition of a PI3K is a mechanism for Rho 
suppression by the inhibitors. Notably, the EC50 values of these 
inhibitors for suppression of contraction and Rho were higher 
than those previously reported for inhibition of PI3K-mediated 
effects including Akt stimulation and cell survival (35). PI3Ks 
are divided into three main classes based on their structure and 
substrate preference (35,36). Class I enzymes are heterodimers 
of the catalytic subunits including p110α, p110β, p110γ and 
p110δ and the regulatory subunits including p85 and p101. 
Class I enzymes are rapidly activated by a variety of receptor 
tyrosine kinases and/or G protein-coupled receptors and exert 
such diverse biological activities as cell proliferation, survival, 
motility and control of carbohydrate metabolism. Previous 
studies identified Akt as an important downstream effector of
class I PI3Ks (36). Class II enzymes include PI3K-C2α, -β, 
and -γ isoforms. It is poorly understood how their activities are 
regulated and what physiological functions they serve. Class 
III enzyme, a homologue of yeast Vps34p, plays an important 
role in vesicular trafficking. LY294002 and wortmannin
inhibit these PI3K enzymes with similar potencies, except 
PI3K-C2α that is at least one order less sensitive to either of 
PI3K inhibitors (35,37). In vascular smooth muscle, at least 4 
PI3K isoforms, class I p110α and p110β, class II PI3K-C2α, 
and PI3K-C2β, were detected. We immunoprecipitated each 
of p110α, p110β and PI3K-C2α from vascular smooth muscle, 
and determined their sensitivities to wortmannin. We found 
that PI3K-C2α was less sensitive to wortmannin than p110α 
and p110β. This observation suggested that PI3K-C2α might 
mediate Rho activation and contraction. To directly test this 
possibility, we examined the effect of small interfering RNA 
(siRNA)-mediated PI3K-C2α down-regulation on contraction 
Figure 3. The dual roles of Ca2+ in MLC phosphorylation. Ca2+ not only activates MLCK but also induces Rho activation through 
a mechanism involving PI3K-C2α. Rho activation induces MP inhibition, which in cooperation with MLCK causes effective MLC 
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in vascular smooth muscle cells. The vascular smooth muscle 
cells, which are enzymatically dispersed from aortic media 
and cultured in the serum-free chemically defined medium,
maintain contractile responses to various vasoactive substances 
including noradrenaline (38). Down-regulation of PI3K-C2α 
by approximately 70% inhibited noradrenaline-induced 
contraction and MYPT1 phosphorylation (34). In contrast, 
down-regulation of p110α did not inhibit noradrenaline-
induced contraction or MYPT1 phosphorylation. These 
observations indicate that PI3K-C2α is involved in Ca2+-
dependent Rho activation and resultant negative regulation of 
MP, thus contributing to MLC phosphorylation and contraction 
(Fig. 3). This is the first demonstration of the novel role of
class II PI3K in the regulation of vascular system
The discovery of the Ca2+-dependent Rho activation 
suggests that membrane depolarization induces Rho-dependent 
MP inhibition in vivo. Smooth muscle is depolarized by 
excitatory receptor agonists and mechanical strains (39). 
Vascular smooth muscle is constantly exposed to stretch 
derived from the intravascular pressure. Stretch of vascular 
smooth muscle induces gating of cation channels, resulting 
in membrane depolarization and stimulation of Ca2+ influx
through voltage-dependent Ca2+ channels. Likely, the resultant 
increase of [Ca2+]i activates not only MLCK but also Rho, 
the latter of which leads to MP inhibition and potentiation of 
MLC phosphorylation and thereby contraction. We observed 
that intravenous wortmannin infusion induced a decrease in 
the arterial blood pressure with inhibition of arterial PI3K-
C2α activity, Rho activity and MYPT1 phosphorylation (34), 
suggesting that PI3K-C2α-dependent Rho and MP regulation 
is operating in the blood vessel in vivo. Thus, Ca2+-dependent 
Rho activation likely contributes to vascular tone regulation. 
CONCLUSION
Since we first reported in 1995 that agonist-induced Ca2+ 
sensitization of smooth muscle MLC phosphorylation and 
contraction involves Rho-dependent inhibition of myosin 
phosphatase (8), great progress has been made in understanding 
the mechanisms of Rho-dependent Ca2+sensitization. 
Excitatory receptor agonists, most of which act on heptahelical 
G protein-coupled receptors, stimulate Rho through multitudes 
of mechanisms involving G12/13 and Gq-Ca2+ (11). The Ca2+-
dependent mechanism has thus far been unrecognized in non-
muscle cells and may be unique to smooth muscle. Activation 
of Rho phosphorylates the regulatory subunit MYPT1 of MP 
via Rho kinase (6). Rho kinase may also phosphporylate to 
activate the MP inhibitor phosphoprotein CPI-17 (5). Recent 
studies demonstrated the possibilities that several other serine/
threonine kinases may also be involved in phosphorylation 
of both MYPT1 and CPI-17, and thus in the regulation of 
MP activity (5,6). Consistent with the roles for Rho kinase 
in agonist-induced contraction, Rho kinase inhibitors reduce 
agonist-induced contraction. These observations support the 
model for the signaling of agonist-induced contraction, in 
which activation of receptors by excitatory agonists triggers 
Ca2+ mobilization and consequent activation of MLCK via Gq, 
as well as Rho-Rho kinase-dependent inhibition of MP via 
G12/13 and Gq. The activation of MLCK and inhibition of MP 
operate in concert to result in efficient phosphorylation of MLC
and contraction (Fig. 3). Protein kinase C was recently shown 
to be involved in inhibition of MP through phosphorylation of 
CPI-17. However, a number of previous studies also suggested 
that protein kinase C contributes to contraction in a manner 
independent of MLC phosphorylation (1,3). Thus, the protein 
kinase C branch of the Gq-signaling may regulate both MLC 
phosphorylation-dependent and -independent mechanisms of 
contraction.
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